MX2019011656A - Formatos mejorados de receptor de union a antigeno. - Google Patents
Formatos mejorados de receptor de union a antigeno.Info
- Publication number
- MX2019011656A MX2019011656A MX2019011656A MX2019011656A MX2019011656A MX 2019011656 A MX2019011656 A MX 2019011656A MX 2019011656 A MX2019011656 A MX 2019011656A MX 2019011656 A MX2019011656 A MX 2019011656A MX 2019011656 A MX2019011656 A MX 2019011656A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen binding
- present
- binding receptor
- antigen
- relates
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 8
- 102000036639 antigens Human genes 0.000 title abstract 8
- 108091007433 antigens Proteins 0.000 title abstract 8
- 230000027455 binding Effects 0.000 title abstract 6
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Abstract
La presente invención se refiere de manera general a receptores de unión a antígeno en formatos nuevos capaces de unión específica a un antígeno asociado a tumor. Más exactamente, la presente invención se refiere a un receptor de unión a antígeno que se une/interactúa eficiente y específicamente con un antígeno sobre la superficie de una célula tumoral, y con una célula T transfectada/transducida con el receptor de unión a antígeno. Además, la invención se refiere a moléculas de ácidos nucleicos y vectores codificantes de receptores de unión a antígeno de la presente invención. La invención proporciona además la producción y uso de células T en un método para el tratamiento de enfermedades particulares, así como composiciones/medicamentos farmacéuticos que comprenden receptores de unión a antígeno y/o células T de la presente invención.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17163090 | 2017-03-27 | ||
EP17171775 | 2017-05-18 | ||
PCT/EP2018/057567 WO2018177967A1 (en) | 2017-03-27 | 2018-03-26 | Improved antigen binding receptor formats |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019011656A true MX2019011656A (es) | 2019-12-02 |
Family
ID=61800534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019011656A MX2019011656A (es) | 2017-03-27 | 2018-03-26 | Formatos mejorados de receptor de union a antigeno. |
Country Status (19)
Country | Link |
---|---|
US (1) | US20200093861A1 (es) |
EP (1) | EP3600408A1 (es) |
JP (1) | JP2020511979A (es) |
KR (1) | KR20190133017A (es) |
CN (1) | CN110461360A (es) |
AU (1) | AU2018241625A1 (es) |
BR (1) | BR112019017629A2 (es) |
CA (1) | CA3054104A1 (es) |
CL (1) | CL2019002686A1 (es) |
CR (1) | CR20190431A (es) |
IL (1) | IL268824A (es) |
MA (1) | MA49355A (es) |
MX (1) | MX2019011656A (es) |
PE (1) | PE20191703A1 (es) |
RU (1) | RU2019133199A (es) |
SG (1) | SG11201908784TA (es) |
TW (1) | TW201900672A (es) |
WO (1) | WO2018177967A1 (es) |
ZA (1) | ZA201905519B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
ES2897217T3 (es) * | 2016-09-30 | 2022-02-28 | Hoffmann La Roche | Anticuerpos biespecíficos frente a p95HER2 |
CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技(香港)有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
RU2019133202A (ru) | 2017-03-27 | 2021-04-28 | Ф. Хоффманн-Ля Рош Аг | Улучшенные антигенсвязывающие рецепторы |
AU2019410073A1 (en) | 2018-12-21 | 2021-06-10 | F. Hoffmann-La Roche Ag | Tumor-targeted agonistic CD28 antigen binding molecules |
TW202030204A (zh) * | 2018-12-21 | 2020-08-16 | 瑞士商赫孚孟拉羅股份公司 | 靶向腫瘤之超促效cd28抗原結合分子 |
CN110317277A (zh) * | 2019-07-10 | 2019-10-11 | 杭州普科亭生物医药有限公司 | 嵌合抗原受体及其应用 |
JP2023523988A (ja) * | 2020-04-30 | 2023-06-08 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | Her2を標的とする抗原結合構築物及び用途 |
IL300500A (en) | 2020-08-20 | 2023-04-01 | A2 Biotherapeutics Inc | Preparations and methods for the treatment of mesothelin positive cancer |
IL300497A (en) * | 2020-08-20 | 2023-04-01 | A2 Biotherapeutics Inc | Compositions and methods for treating CEACAM-positive cancer |
CN114990129B (zh) * | 2022-05-11 | 2023-02-03 | 北京贝来生物科技有限公司 | 表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
DE69434447T2 (de) | 1993-06-07 | 2006-05-18 | Vical, Inc., San Diego | Für die gentherapie verwendbare plasmide |
CA2225460A1 (en) | 1995-06-23 | 1997-01-09 | Winston Campbell Patterson | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
CA2393869A1 (en) | 1999-12-15 | 2001-06-21 | Genetech,Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック, インコーポレイテッド | 合成抗体ファージライブラリー |
WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
EP2402374A1 (en) | 2005-02-07 | 2012-01-04 | GlycArt Biotechnology AG | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
AU2007249408A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US20110280894A1 (en) | 2008-07-31 | 2011-11-17 | Angela Krackhardt | Her2/neu specific t cell receptors |
BR112013018311A2 (pt) * | 2011-01-18 | 2017-03-21 | Univ Pennsylvania | sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada. |
EP3590965A1 (en) | 2011-03-29 | 2020-01-08 | Roche Glycart AG | Antibody fc variants |
HUE038225T2 (hu) | 2011-08-23 | 2018-10-29 | Roche Glycart Ag | Bispecifikus, T-sejtaktiváló antigénkötõ, molekulák |
US10633451B2 (en) * | 2012-02-03 | 2020-04-28 | Hoffmann-La Roche Inc. | Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine |
US9598489B2 (en) * | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
WO2015142661A1 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
US20170151283A1 (en) * | 2014-05-23 | 2017-06-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating antibody resistance |
KR102485855B1 (ko) * | 2014-06-06 | 2023-01-09 | 2세븐티 바이오, 인코포레이티드 | 개선된 t 세포 조성물 |
WO2016020309A1 (en) | 2014-08-04 | 2016-02-11 | F. Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
MA40595A (fr) * | 2014-09-09 | 2021-05-26 | Unum Therapeutics | Récepteurs chimériques et utilisations de ceux-ci en thérapie immunitaire |
WO2016126608A1 (en) * | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
CN114990141A (zh) | 2015-05-15 | 2022-09-02 | 希望之城 | 嵌合抗原受体组合物 |
JP2018526013A (ja) * | 2015-09-01 | 2018-09-13 | イネイト・テューマー・イミュニティ・インコーポレイテッドInnate Tumor Immunity, Inc. | 免疫または免疫抑制性サイトカインに対する抵抗性が増大した免疫細胞およびその使用 |
CN109311994B (zh) * | 2015-10-01 | 2022-06-07 | 药物研究及发展中心 | 抗足糖萼蛋白抗体及其使用方法 |
JP7231158B2 (ja) * | 2016-10-19 | 2023-03-01 | ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント | Cd133結合剤およびその使用 |
JOP20180027A1 (ar) * | 2017-03-28 | 2019-01-30 | Cell Design Labs Inc | بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها |
-
2018
- 2018-03-26 WO PCT/EP2018/057567 patent/WO2018177967A1/en unknown
- 2018-03-26 KR KR1020197030317A patent/KR20190133017A/ko not_active Application Discontinuation
- 2018-03-26 PE PE2019001939A patent/PE20191703A1/es unknown
- 2018-03-26 CN CN201880021542.3A patent/CN110461360A/zh active Pending
- 2018-03-26 RU RU2019133199A patent/RU2019133199A/ru unknown
- 2018-03-26 CR CR20190431A patent/CR20190431A/es unknown
- 2018-03-26 JP JP2019552992A patent/JP2020511979A/ja active Pending
- 2018-03-26 SG SG11201908784T patent/SG11201908784TA/en unknown
- 2018-03-26 BR BR112019017629A patent/BR112019017629A2/pt not_active IP Right Cessation
- 2018-03-26 EP EP18713648.6A patent/EP3600408A1/en not_active Withdrawn
- 2018-03-26 CA CA3054104A patent/CA3054104A1/en active Pending
- 2018-03-26 TW TW107110206A patent/TW201900672A/zh unknown
- 2018-03-26 AU AU2018241625A patent/AU2018241625A1/en not_active Abandoned
- 2018-03-26 MX MX2019011656A patent/MX2019011656A/es unknown
- 2018-03-26 MA MA049355A patent/MA49355A/fr unknown
-
2019
- 2019-08-21 ZA ZA2019/05519A patent/ZA201905519B/en unknown
- 2019-08-21 IL IL26882419A patent/IL268824A/en unknown
- 2019-09-19 US US16/576,586 patent/US20200093861A1/en not_active Abandoned
- 2019-09-23 CL CL2019002686A patent/CL2019002686A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2020511979A (ja) | 2020-04-23 |
RU2019133199A (ru) | 2021-04-28 |
CR20190431A (es) | 2019-11-01 |
CA3054104A1 (en) | 2018-10-04 |
TW201900672A (zh) | 2019-01-01 |
CL2019002686A1 (es) | 2020-02-14 |
MA49355A (fr) | 2020-02-05 |
PE20191703A1 (es) | 2019-11-27 |
EP3600408A1 (en) | 2020-02-05 |
BR112019017629A2 (pt) | 2020-04-07 |
CN110461360A (zh) | 2019-11-15 |
AU2018241625A1 (en) | 2019-09-05 |
RU2019133199A3 (es) | 2021-07-09 |
SG11201908784TA (en) | 2019-10-30 |
KR20190133017A (ko) | 2019-11-29 |
IL268824A (en) | 2019-10-31 |
WO2018177967A1 (en) | 2018-10-04 |
US20200093861A1 (en) | 2020-03-26 |
ZA201905519B (en) | 2021-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019011656A (es) | Formatos mejorados de receptor de union a antigeno. | |
MX2020001198A (es) | Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos. | |
PH12021550307A1 (en) | T Cell Receptor Constructs And Uses Thereof | |
ZA201905822B (en) | Antibodies against pd-l1 | |
MX349396B (es) | Moleculas de union para bcma y cd3. | |
EA202091566A1 (ru) | Содержащая нуклеиновую кислоту липидная наночастица и ее применение | |
MX2018010733A (es) | Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas. | |
MX2017001403A (es) | Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido. | |
MX2022015821A (es) | Nuevos receptores de celulas t y usos de los mismos. | |
ZA202100676B (en) | Anti-tigit antibody and uses thereof | |
WO2018132739A3 (en) | T cell receptors that bind to ny-eso-1 and methods of use thereof | |
MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
TN2017000551A1 (en) | Antibody constructs for cd70 and cd3. | |
MX2019006724A (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza. | |
BR112015019603A2 (pt) | Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna | |
PH12015501672A1 (en) | Binding molecules for bcma and cd3 | |
MX366965B (es) | Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina. | |
GB2549632A8 (en) | Fusion protein comprising three binding domains to 5T4 and CD3 | |
WO2018191502A3 (en) | Anti-cd137 antibodies and methods of use thereof | |
PH12015501651A1 (en) | Antibody constructs for cdh19 and cd3 | |
NZ722076A (en) | Chimeric antigen receptor containing a toll-like receptor intracellular domain | |
WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
ZA202201464B (en) | Anti-tigit antibodies and application thereof | |
MX2022000242A (es) | Anticuerpos contra ticagrelor y metodos de uso. | |
PH12014502182A1 (en) | Methods and compositions for modulating notch activity |